Skip to content

Zymeworks ZYME Net Investment in Lease

Net Investment in Lease at other companies

AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
Septerna, Inc. logo
Septerna, Inc.SEPN

Other financials

Income statement

See full
Revenue$2.4M-91.1%
Operating income-$47.1M-84.0%
Net income-$44.2M-95.1%
EPS (diluted)-$0.59-96.7%

Balance sheet

See full
Cash & equivalents$244.3M+221%
Total debt$17.0M-7.7%
Total equity$163.6M-49.7%
Total assets$478.2M+12.4%

Cash flow

See full
Operating cash flow-$45.7M-1,242%
CapEx$216.0K+1,250%
Free cash flow-$45.9M-1,242%

Valuation

See full
Market cap$1.79B+125%

Profitability

See full
Operating margin-140.4%+7.3pp
Net margin-126.3%+5.0pp
FCF margin-94.8%+15.5pp

Returns & leverage

See full
Return on equity-42%+29.2pp
Debt / equity0.1×0.0×
Current ratio10.8×+6.1×

Where this comes from

Reported directly by Zymeworks in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: Zymeworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zymeworks's net investment in lease.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Zymeworks's net investment in lease?
Zymeworks (ZYME) reported net investment in lease of $14.02M in Q1 2026.
How has Zymeworks's net investment in lease changed year-over-year?
Zymeworks's net investment in lease decreased by 16.2% year-over-year, from $16.72M to $14.02M.
What is the long-term trend for Zymeworks's net investment in lease?
Over 4 years (2021 to 2025), Zymeworks's net investment in lease has grown at a -12.6% compound annual growth rate (CAGR), from $26.99M to $15.72M.